drugset / Trial / NCT01634087

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

NCT01634087

Phase 2 Completed 50 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

Timeline

Start
2012-06
Primary completion
2013-01
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule 100 mg Oral
Subject Itacitinib Small molecule 200 mg Oral
Subject Itacitinib Small molecule 600 mg Oral

Indications